VITAGLP

Enrolling by invitationPhase NA

Multivitamin Impact on Micronutrient Status in GLP-1 Users: A Randomized Trial

The Impact of Multivitamin Supplementation on Micronutrient Levels in GLP-1 Users: A Randomized, Double-Blind, Placebo-Controlled Trial

Lead sponsor

Erasmus Medical Center

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Estimated enrollment

246

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥30

Primary endpoint

•Serum levels

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07234916

Org study IDGLP-1-RCT-2025

Secondary IDABR 2025 GLPThe Netherlands Medical Research Portal (CCMO)

Timeline

Milestones

Study first posted2025-11-19actual

Last update posted2025-11-19actual

Study start2025-12-16estimated

Primary completion2027-03-16estimated

Study completion2027-04-30estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Age ≥18 to 70 years.

•Start with the use of Tirzepatide GLP-1 receptor agonists and for at least 3 months with stable dosing before randomization.

•BMI ≥30 kg/m² or ≥27 kg/m² with obesity-associated medical problems (such as type 2 diabetes, hypertension, or dyslipidemia) at the start of GLP-1 therapy

•Willing and able to provide informed consent

•Able to comply with study procedures and follow-up visits

•Own vitamins should be completely discontinued 2 weeks before the start

Exclusion criteria

•Known allergy or hypersensitivity to any components of the multivitamin supplement

•Current use of other vitamin or mineral supplements

•Pregnancy or planning pregnancy during the study period

•Patients who follow a vegan diet.

•Active malignancy or ongoing cancer treatment

•Severe kidney disease (eGFR <30 mL/min/1.73m²)

•Severe liver disease (Child-Pugh C)

•History of metabolic bariatric surgery

•Participation in other clinical trials within the past 3 months

•Any condition that, in the investigator's opinion, would interfere with study participation or compromise patient safety

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Weight & body composition

Other clinical outcomes

Weight & body composition

2 endpoints

Other/protocol endpoint

Weight loss

Time frame:12 months

descriptive

Other/protocol endpoint

Body composition assessment

Time frame:12 months

descriptive

Other clinical outcomes

1 endpoint

Other/protocol endpoint

GLP adherence

Time frame:12 months

descriptive

Other (unclassified)

5 endpoints

Primary/protocol endpoint/low confidence

serum levels

Time frame:15 months

descriptive

Secondary/protocol endpoint/low confidence

other micronutrient levels

Time frame:12 months

descriptive

Other/protocol endpoint/low confidence

diet

Time frame:12 months

descriptive

Other/protocol endpoint/low confidence

QoL

Time frame:12 months

descriptive

Other/protocol endpoint/low confidence

Resting Energy Expenditure (REE)

Time frame:12 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.